- Condition: Hepatitis C Virus
Interventions: Biological: Peginterferon Lambda-1a; Biological: Peginterferon Alfa-2a; Drug: Ribavirin; Drug: Telaprevir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified May 2012 - Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: Imatinib; Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified May 2012 - Conditions: Non-Hodgkin's Lymphoma; Hodgkin Lymphoma; Multiple Myeloma; Chronic Myelogenous Leukemia
Intervention: Biological: BMS-936558 (Anti-PD-1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified May 2012 - Condition: Chronic Hepatitis B
Interventions: Drug: Group A (Zeffix, Sebivo, Hepsera); Drug: Group B (Baraclude, Viread)
Sponsors: Yonsei University; Yonsei University; Bristol-Myers Squibb; Asan Medical Center; Seoul St. Mary's Hospital; Soonchunhyang University Hospital; Pusan National University Hospital; Kyungpook National University; Hallym University Medical Center; Chonbuk National University Hospital
Not yet recruiting - verified May 2012 - Condition: Chronic Hepatitis B
Intervention: Drug: Entecavir + Tenofovir (MDR group)
Sponsors: Yonsei University; Yonsei University; Bristol-Myers Squibb; Asan Medical Center; Seoul St. Mary's Hospital
Not yet recruiting - verified May 2012 - Condition: Atherosclerosis
Interventions: Drug: BMS-962476; Drug: BMS-962476; Drug: BMS-962476; Drug: BMS-962476; Drug: BMS-962476; Drug: BMS-962476; Drug: BMS-962476; Drug: BMS-962476; Drug: Placebo matching with BMS-962476; Drug: Placebo matching with BMS-962476
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified April 2012 - Condition: Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
Interventions: Biological: Ipilimumab; Other: Best Supportive care (BSC)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention: Drug: No Intervention (subjects were previously treated with Orencia®)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified April 2012 - Condition: Hepatitis C Virus
Interventions: Drug: Asunaprevir (ASV); Drug: Daclatasvir (DCV); Drug: PBO matching ASV; Drug: Placebo (PBO) matching DCV; Drug: Pegylated-interferon alfa 2a (PegIFN); Drug: Ribavirin (RBV)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified April 2012 - Condition: Melanoma
Intervention: Drug: Ipilimumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Not yet recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Intervention: Drug: No Intervention (subjects were previously treated with Onglyza®)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Hepatitis C Virus
Interventions: Drug: Asunaprevir; Drug: Daclatasvir; Drug: Peg-interferon Alfa-2a; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified April 2012 - Condition: Hepatitis C
Intervention:
Sponsors: Peking University People's Hospital; Peking University People's Hospital; Bristol-Myers Squibb
Recruiting - verified May 2012 - Conditions: Mental Disorders; Worries; Pain or Disability
Intervention: Behavioral: Progressive Goal Attainment Program
Sponsors: MDRC; MDRC; VA Connecticut Healthcare System; Michael Debakey Veterans Affairs Medical Center; The Boeing Company; Bristol-Myers Squibb; The Community Foundation for Greater New Haven; Disabled American Veterans
Recruiting - verified March 2012 - Condition: Crohn's Disease
Interventions: Biological: Placebo matching with BMS-945429; Biological: Placebo matching with BMS-945429; Biological: Placebo matching with BMS-945429; Biological: Placebo matching with BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified March 2012 - Condition: Hepatocellular Carcinoma
Intervention: Drug: Brivanib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Arthritis, Rheumatoid
Intervention: Drug: Abatacept
Sponsors: Arthritis Northwest PLLC; Arthritis Northwest PLLC; Bristol-Myers Squibb
Active, not recruiting - verified March 2012 - Condition: Type 2 Diabetes Mellitus (T2D)
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified March 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Metformin IR; Drug: Saxagliptin; Drug: Metformin IR; Drug: Saxagliptin/Metformin XR FDC; Drug: Metformin XR
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Not yet recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca; Parexel
Not yet recruiting - verified April 2012 - Condition: Chronic Hepatitis C
Interventions: Drug: BMS-929075; Drug: BMS-929075; Drug: BMS-929075; Drug: BMS-929075; Drug: Placebo matching BMS-929075; Drug: Placebo matching BMS-929075
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified January 2012 - Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Ipilimumab and GM-CSF
Sponsors: University of California, San Francisco; University of California, San Francisco; Bristol-Myers Squibb; Genzyme
Not yet recruiting - verified February 2012 - Condition: Type 2 Diabetes
Intervention:
Sponsors: China Cardiometabolic Registries; China Cardiometabolic Registries; Bristol-Myers Squibb; VitalStrategic Research Institute
Not yet recruiting - verified February 2012 - Conditions: Type 2 Diabetes; Hypertriglyceridemia
Intervention: Drug: Saxagliptin
Sponsors: Oregon Health and Science University; Oregon Health and Science University; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Urothelial Carcinoma
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Ipilimumab
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bristol-Myers Squibb
Recruiting - verified March 2012 - Conditions: Carcinoma, Non-small Cell Lung; Melanoma
Intervention: Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified February 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: BMS-823778; Drug: BMS-823778; Drug: BMS-823778; Drug: BMS-823778; Drug: Placebo matching with BMS-823778
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2012 - Condition: Healthy Volunteers
Interventions: Drug: BMS-754807 (IGR-IR/IR Inhibitor); Drug: Metformin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Completed - verified May 2012 - Condition: Melanoma
Interventions: Biological: Ipilimumab; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012 - Conditions: Bipolar Disorder; Depressive Episode
Interventions: Drug: Low dose Adjunctive Aripiprazole; Drug: placebo
Sponsors: Douglas Mental Health University Institute; Serge Beaulieu; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Hepatitis C
Intervention: Drug: BMS-914143
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Healthy
Intervention: Drug: Clopidogrel
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified January 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Dapagliflozin + Glucophage tablet fasted; Drug: Dapagliflozin/metformin IR FDC tablet fasted; Drug: Dapagliflozin + Glucophage tablet fed; Drug: Dapagliflozin/metformin IR FDC tablet fed
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb
Withdrawn - verified April 2012 - Condition: HIV-1 Infection
Intervention: Drug: Atazanavir/ritonavir monotherapy
Sponsors: Fondazione SanRaffaele del Monte Tabor; Fondazione SanRaffaele del Monte Tabor; Bristol-Myers Squibb
Recruiting - verified January 2012 - Condition: Fasting
Intervention: Drug: Clopidogrel
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified January 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2012 - Condition: Hepatitis C
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Telaprevir; Drug: Peginterferon alfa-2a; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Alzheimer's Disease
Interventions: Drug: BMS-241027; Drug: BMS-241027; Drug: BMS-241027; Drug: Placebo matching BMS-241027
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Decitabine; Drug: Decitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Not yet recruiting - verified April 2012 - Condition: HIV-1 Infection
Interventions: Drug: BMS-986001; Drug: BMS-986001; Drug: BMS-986001; Drug: Placebo matching with BMS-986001; Drug: Efavirenz; Drug: Lamivudine; Drug: Tenofovir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: Melanoma
Interventions: Biological: BMS-982470 (recombinant interleukin-21); Biological: BMS-982470 (recombinant interleukin-21); Biological: BMS-982470 (recombinant interleukin-21); Biological: BMS-982470 (recombinant interleukin-21); Biological: Ipilimumab; Biological: Ipilimumab; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Conditions: Premature Endothelial Dysfunction; Rheumatoid Arthritis; Healthy
Intervention:
Sponsors: Orrin M Troum, M.D. and Medical Associates; Orrin M Troum, M.D. and Medical Associates; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: End-Stage Renal Disease
Intervention: Drug: Belatacept
Sponsors: University of Maryland; University of Maryland; Bristol-Myers Squibb
Not yet recruiting - verified December 2011 - Condition: Hepatitis C
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: BMS-650032 (Asunaprevir)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified January 2012 - Condition: Hepatitis C
Intervention: Drug: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Metformin; Behavioral: Dietary Restriction; Behavioral: Exercise Training
Sponsors: Pennington Biomedical Research Center; Pennington Biomedical Research Center; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012 - Condition: Squamous Cell Carcinoma Of The Head And Neck
Interventions: Drug: Cetuximab; Drug: Dasatinib
Sponsors: University of Pittsburgh; University of Pittsburgh; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: Cutaneous Melanoma
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2012 - Condition: Endometrial Cancer
Interventions: Drug: Dasatinib; Drug: Dasatinib
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified January 2012 - Condition: Arthritis, Psoriatic
Interventions: Biological: Placebo matching BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified January 2012 - Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung CancerCondition: Lung Cancer - Non Small Cell
Interventions: Biological: Ipilimumab; Biological: Pemetrexed
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified February 2012 - Condition: Kidney Transplantation
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; University of Heidelberg
Active, not recruiting - verified April 2012 - Condition: Cancer - Solid Tumors
Interventions: Drug: BMS-663513 (Anti-CD137); Drug: BMS-663513 (Anti-CD137); Drug: BMS-663513 (Anti-CD137)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2011 - Condition: Transplantation, Organ
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; University of Heidelberg
Active, not recruiting - verified April 2012 - Condition: Hepatitis C, Genotype 1
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Ribavirin; Drug: Peg-Interferon alfa 2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Crohn's Disease
Interventions: Drug: Placebo; Drug: Placebo; Drug: BMS-936557 (Anti-IP-10 Antibody); Drug: BMS-936557 (Anti-IP-10 Antibody); Drug: BMS-936557 (Anti-IP-10 Antibody); Drug: BMS-936557 (Anti-IP-10 Antibody); Drug: BMS-936557 (Anti-IP-10 Antibody)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012 - Conditions: Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Drug: Sunitinib; Drug: Pazopanib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Company, Ltd.
Recruiting - verified March 2012 - Condition: Leukemia, Pediatric
Intervention: Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Children's Oncology Group; EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Recruiting - verified April 2012 - Condition: Stage III or IV Melanoma
Interventions: Biological: BMS-936559 (Anti-PD-L1); Biological: BMS-936559 (Anti-PD-L1); Biological: BMS-936559 (Anti-PD-L1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Withdrawn - verified October 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-790052; Drug: BMS-790052; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2011 - Condition: HIV-1
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012 - Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified October 2011 - Conditions: Leukemia, Myelomonocytic, Chronic; Leukemia-Lymphoma
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012 - Condition: Alzheimer's Disease
Interventions: Drug: BMS-708163 (Gamma-Secretase Inhibitor); Drug: BMS-708163 (Gamma-Secretase Inhibitor); Drug: BMS-708163 (Gamma-Secretase Inhibitor); Drug: BMS-708163 (Gamma-Secretase Inhibitor); Drug: BMS-708163 (Gamma-Secretase Inhibitor); Drug: BMS-708163 (Gamma-Secretase Inhibitor); Drug: BMS-708163 (Gamma-Secretase Inhibitor); Drug: BMS-708163 (Gamma-Secretase Inhibitor); Drug: BMS-708163 (Gamma-Secretase Inhibitor); Drug: BMS-708163 (Gamma-Secretase Inhibitor); Drug: Placebo matching BMS-708163; Drug: Placebo matching BMS-708163
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Completed - verified November 2011 - Condition: Hepatitis C
Interventions: Drug: BMS-790052 (NS5A Replication Complex Inhibitor); Drug: Placebo matching BMS-790052; Drug: Pegylated-interferon alfa 2a; Drug: Pegylated-interferon alfa 2a; Drug: Ribavirin; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: Hepatitis C Virus (HCV)
Interventions: Biological: Pegylated Interferon Lambda; Biological: Pegylated Interferon Alfa-2a; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Withdrawn - verified February 2012 - Conditions: Non-Hodgkin's Lymphoma; Hodgkin Lymphoma; Multiple Myeloma; Chronic Myelogenous Leukemia
Intervention: Biological: BMS-936559 (Anti PD-L1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Withdrawn - verified February 2012 - Condition: Migraine
Interventions: Drug: BMS-927711 (CGRP Antagonist); Drug: BMS-927711 (CGRP Antagonist)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2011 - Condition: Smoldering Multiple Myeloma
Intervention: Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012 - Condition: Rheumatoid Arthritis
Intervention: Biological: Abatacept (BMS-188667)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Completed - verified February 2012 - Condition: HIV
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Active, not recruiting - verified December 2011 - Condition: Recurrent Endometrial Cancer
Intervention: Drug: Lapatinib and ixempra
Sponsors: Chang Gung Memorial Hospital; Hung-Hsueh Chou; GlaxoSmithKline; Bristol-Myers Squibb
Enrolling by invitation - verified October 2011 - Conditions: Hepatitis B Virus; HBV
Intervention: Drug: entecavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Completed - verified September 2011 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: Gemcitabine; Drug: Cisplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo matching with Saxagliptin; Drug: Metformin IR; Drug: Metformin XR; Drug: Saxagliptin; Drug: Saxagliptin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Not yet recruiting - verified February 2012 - Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Dasatinib
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; Bristol-Myers Squibb
Active, not recruiting - verified October 2011 - Condition: Migraine - Acute
Interventions: Drug: Placebo matching BMS-927711; Drug: BMS-927711; Drug: BMS-927711; Drug: BMS-927711; Drug: BMS-927711; Drug: BMS-927711; Drug: BMS-927711; Drug: Sumatriptan
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Active, not recruiting - verified May 2012 - Condition: Dementia, Alzheimer Type
Interventions: Drug: Aripiprazole (BMS-337039); Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Otsuka America Pharmaceutical
Completed - verified March 2012 - Condition: Hepatitis C Virus
Interventions: Drug: BMS-790052 (HCV NS5A Replication Co-factor Inhibitor); Drug: BMS-650032 (HCV NS3 Protease Inhibitor); Drug: Peginterferon alfa-2a; Drug: Ribavirin; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Hepatitis C
Interventions: Drug: INX-08189; Drug: INX-08189; Drug: INX-08189; Drug: Placebo matching with INX-08189; Biological: Pegylated interferon alfa-2a; Drug: Ribavirin; Drug: INX-08189; Drug: Daclatasvir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Active, not recruiting - verified May 2012 - Condition: Metastatic Breast Cancer
Intervention: Drug: paclitaxel plus trastuzumab
Sponsors: WiSP Wissenschaftlicher Service Pharma GmbH; WiSP Wissenschaftlicher Service Pharma GmbH; Bristol-Myers Squibb GmbH; Roche Pharma AG
Completed - verified August 2011 - Condition: Cancer
Intervention: Drug: BMS-833923 (XL139)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: HIV
Interventions: Drug: Atazanavir; Drug: Atazanavir; Drug: Atazanavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Completed - verified September 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: BMS-817399; Drug: BMS-817399
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012 - Conditions: Severe Mental Illness; Nicotine Dependence
Interventions: Behavioral: Electronic decision support system with CO monitor feedback; Behavioral: Electronic decision support system without CO monitor feedback
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center; U.S. Department of Education; Bristol-Myers Squibb
Recruiting - verified March 2012 - Condition: Melanoma
Interventions: Drug: Ipilimumab (BMS-734016); Biological: Vemurafenib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Roche-Genentech
Recruiting - verified November 2011 - Condition: Depression
Interventions: Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836; Drug: Placebo matching BMS-820836; Drug: BMS-820836
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified August 2011 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Drug: Lenalidomide; Drug: Lenalidomide
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011 - Condition: Leukemia
Interventions: Drug: Dasatinib (BMS-354825); Drug: Dasatinib (BMS-354825); Drug: Dasatinib (BMS-354825)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Completed - verified April 2012 - Conditions: Liver Failure; Liver Failure, Acute; Liver Diseases; Carcinoma, Hepatocellular; Liver Neoplasms
Intervention: Drug: N-acetylcystein
Sponsors: Azienda Ospedaliera di Padova; Azienda Ospedaliera di Padova
Completed - verified September 2011 - Condition: Chronic Myeloid Leukemia
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Active, not recruiting - verified July 2011 - Condition: Hepatitis C
Interventions: Drug: BMS-790052 (NS5A Replication Complex Inhibitor); Drug: Peg-Interferon Alfa-2a; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: HIV Infection
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; PENTA Foundation
Recruiting - verified March 2012 - Conditions: Type 2 Diabetes Mellitus; High HbA1c Level; Inadequate Glycaemic Control
Interventions: Drug: dapagliflozin; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb
Recruiting - verified May 2012 - Condition: Kidney Transplantation
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Parexel
Recruiting - verified March 2012 - Condition: Human Immunodeficiency Virus-1
Interventions: Drug: BMS-663068; Drug: BMS-663068; Drug: BMS-663068; Drug: BMS-663068; Drug: Raltegravir; Drug: Raltegravir; Drug: Tenofovir; Drug: Tenofovir; Drug: Ritonavir; Drug: Atazanavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca; University of Pennsylvania
Active, not recruiting - verified December 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: BMS-945429 Placebo; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Drug: Methotrexate; Drug: Methotrexate; Drug: Methotrexate Placebo; Drug: Methotrexate; Drug: Adalimumab Placebo; Drug: Adalimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified January 2012 - Condition: Depression
Interventions: Drug: Duloxetine; Drug: Escitalopram; Drug: BMS-820836 Placebo; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified August 2011 - Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Leuprolide; Drug: Goserelin; Drug: Degarelix
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Active, not recruiting - verified April 2012 - Condition: Atazanavir
Interventions: Drug: atazanavir; Drug: Atazanavir(ATZ) and Tenofovir(TDF); Drug: Atazanavir(ATZ) + Ritonavir; Drug: atazanavir(ATZ) + tenofovir(TDF) + ritonavir
Sponsors: Asan Medical Center; Asan Medical Center; Bristol-Myers Squibb
Not yet recruiting - verified May 2011 - Conditions: Colorectal Cancer; Colorectal Adenocarcinoma
Interventions: Drug: Brivanib; Drug: Irinotecan
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified May 2012
 |
Bristol-Myers Squibb - Database of Clinical Trials by Pharmaceutical Companies |
